Experiment 631389
Worktypes
Compounds isolated
Details
| Property | Value |
|---|---|
| Pharmacology | |
| Administration route | IV |
| Organism | Empty organism |
| Citation | GORDON,M: BIHARI,B: GOOSBY,E: GORTER,R: GRECO,M: GURALNIK,M: MIMURA,T: RUDINICKI,V: WONG,R: KANEKO,Y:. (1998). A PLACEBO-CONTROLLED TRIAL OF THE IMMUNE MODULATOR, LENTINAN, IN HIV-POSITIVE PATIENTS: A PHASE I/II TRIAL.. 29(5/6) |
| Amount utilized | |
| Compound isolated | |
| Disease | 2 PHASE I/II PLACEBO-CONTROLLED TRIALS WAS USED TO STUDY LENTINAN IN HIV POSITIVE PATIENTS. IN THE FIRST STUDY 10 PATIENTS WERE ADMINISTERED 2.5 OR 10 MG OR PLACEBO ONCE A WEEK FOR 8 WEEKS. IN THE SECOND 2 GROUPS OF 20 EACH WERE ADMINISTERED 1 OR 5 MG OF LENTINAN TWICE A WEEK FOR 12 WEEKS AND 10 WERE ADMINISTERED PLACEBO TWICE A WEEK. SIDE EFFECTS WERE MILD. 9 SEVERE SIDE EFFECTS INCLUDED ANAPHYLACTOID REACTION, BACK PAIN, LEG PAIN, DEPRESSION, RIGOR FEVER, CHILLS GRANULOCYTOPENIA. PATIENTS IN THE STUDY SHOWED A TREND TOWARD INCREASES IN CD4 CELLS AND IN SOME PATIENTS NEATIOPHIL ACTIVITY. |
| Dose amount | VAR |
| Number | 1 |
| Qualitative result | ACTIVE |
| Animal | HUMAN ADULT |
| Dose expression | DOSE |
| Gender | GIVEN TO BOTH SEXES |